Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | TNKS | O95271 | 1/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL527788 | 1.00 | HTT (0.57) | HTTNPC1RAB9ATDP1GLA | |
| SCHEMBL527789 | 1.00 | HTT (0.57) | HTTNPC1RAB9ATDP1GLA | |
| SCHEMBL18301511 | 1.00 | HTT (0.57) | HTTNPC1RAB9ATDP1GLA | |
| SCHEMBL527790 | 1.00 | HTT (0.57) | HTTNPC1RAB9ATDP1GLA | |
| SCHEMBL10457952 | 0.80 | RAB9A (0.48) | HTTNPC1RAB9AGLASMN1; SMN2 | |
| SCHEMBL1806526 | 0.79 | OPRM1 (0.44) | HTTALDH1A1MAPTLMNA | |
| SCHEMBL7514017 | 0.79 | NPC1 (0.44) | HTTNPC1RAB9ATDP1GLA | |
| SCHEMBL7514022 | 0.79 | NPC1 (0.44) | HTTNPC1RAB9ATDP1GLA | |
| SCHEMBL11034119 | 0.78 | MAOB (0.44) | HTTNPC1RAB9ATDP1SMN1; SMN2 | |
| SCHEMBL22994501 | 0.75 | SMN1; SMN2 (0.70) | HTTTDP1GLACYP1A2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160022636-A1 | PHYSIOLOGICAL LIGANDS FOR GPR139 | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-28 | — | — | US | claimed |
| EP-2968240-A2 | PHYSIOLOGICAL LIGANDS FOR GPR139 | Janssen Pharmaceutica, N.V. (BE) | 2016-01-20 | — | — | EP | claimed |
| US-20140336216-A1 | PHYSIOLOGICAL LIGANDS FOR GPR139 | JANSSEN PHARMACEUTICA NV (BE) | 2014-11-13 | — | — | US | claimed |
| WO-2014152917-A2 | PHYSIOLOGICAL LIGANDS FOR GPR139 | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-25 | — | — | WO | claimed |
| WO-2011075678-A1 | SPECIFIC INHIBITORS AND ACTIVE SITE PROBES FOR LEGUMAIN | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2011-06-23 | — | — | WO | claimed |
| EP-3303367-B1 | STABILIZED MINIMAL COILED-COIL MIMETICS | UNIV NEW YORK (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2024130161-A2 | NOVEL CAMPTOTHECIN DERIVATIVES AND CONJUGATES THEREOF | BIONECURE THERAPEUTICS INC (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20240124539-A1 | CROSSLINKED HELIX DIMER MIMICS OF SOS AND METHODS OF USING SAME | NEW YORK UNIVERSITY | 2024-04-18 | — | — | US | disclosed |
| US-20240034753-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2024-02-01 | — | — | US | disclosed |
| US-11753445-B2 | Therapeutic peptides | COHBAR, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230218710-A1 | METHOD OF TREATING CORONAVIRUS INFECTIONS | COHBAR, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230137562-A1 | TAU AGGREGATION INHIBITORS | ADRX, INC. | 2023-05-04 | — | — | US | disclosed |
| US-9109007-B2 | MHC-I restricted epitopes containing non-natural amino acid residues | PURDUE PHARMA L.P. (US) | 2015-08-18 | — | — | US | disclosed |
| US-20140336216-A1 | PHYSIOLOGICAL LIGANDS FOR GPR139 | JANSSEN PHARMACEUTICA NV (BE) | 2014-11-13 | — | — | US | disclosed |
| WO-2014152917-A2 | PHYSIOLOGICAL LIGANDS FOR GPR139 | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-25 | — | — | WO | disclosed |
| US-20140050749-A1 | MHC-I Restricted Epitopes Containing Non-Natural Amino Acid Residues | PURDUE PHARMA L.P. (US) | 2014-02-20 | — | — | US | disclosed |
| WO-2012023033-A2 | IMPROVED PEPTIDE IMMUNOGENS | PURDUE PHARMA L.P. (US) | 2012-02-23 | — | — | WO | disclosed |
| WO-2011075678-A1 | SPECIFIC INHIBITORS AND ACTIVE SITE PROBES FOR LEGUMAIN | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2011-06-23 | — | — | WO | disclosed |
| EP-1185869-B1 | LIGAND-ANCHOR CONJUGATES FOR PRODUCING A BIOSENSOR LAYER | GRAFFINITY PHARMACEUTICALS AG (DE) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005105843-A2 | HIV PROTEASE INHIBITORS | ARPIDA A/S (DK) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124539-A1 | CROSSLINKED HELIX DIMER MIMICS OF SOS AND METHODS OF USING SAME | SOS2, SOS1, F2 | HTT 3772/4885NPC1 3848/4885RAB9A 2916/4885 |
| US-20140050749-A1 | MHC-I Restricted Epitopes Containing Non-Natural Amino Acid Residues | MICA, TAP1, CD74 | HTT 1728/4885NPC1 2679/4885RAB9A 4047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.